EGFR and breast carcinoma: On the other hand, FABP5 has been reported to enhance the metastatic potential and tumorigenesis through activation of EGFR signaling pathway in breast cancer [31, 32] and induce the epithelial-mesenchymal transaction (EMT) in hepatocellular cancer [33].